WOS: 000252322200014PubMed ID: 17949428Objectives: Levosimendan is a novel positive inotropic calcium sensitiser agent used in acute left heart failure. In this study, the effect of levosimendan on the right ventricular systolic and diastolic functions was evaluated by tissue Doppler comparing them with dobutamine in patients with ischaemic heart failure. Methods: Patients having an acute decompensated heart failure with ischaemic cardiomyopathy and left ventricular ejection fraction < 40% were included in the study. Before and 24-h after treatment, peak systolic (Sa), peak early (Ea), peak late (Aa) diastolic annular velocities and Ea/Aa ratio from tricuspid lateral annulus by tissue Doppler and systolic pulmonary artery pressure (SPAP) we...
Background: Right ventricular (RV) dysfunction complicates advanced left ventricular (LV) heart fail...
In heart failure, positive inotropes that increase the heart's energy requirements (digoxin, phospho...
Aims: To evaluate the safety and efficacy of levosimendan in patients with left ventricular failure ...
Background: Right ventricular (RV) dysfunction complicates advanced left ventricular (LV) heart fail...
WOS: 000252154900030PubMed ID: 17316845Background: Levosimendan is a novel positive inotropic calciu...
Calcium sensitizers also improve cardiac function by increasing the contraction of the myocardium wi...
Severe heart failure represents a major source of morbidity and mortality. Poor right ventricular fu...
Abstract BACKGROUND: Levosimendan (L) is used in clinical practice for the treatment of severe hear...
BackgroundLevosimendan is a new inodilatory agent with calcium sensitizing activity. A major concern...
International audienceWHAT IS KNOWN AND OBJECTIVE: Positive inotropic agents are frequently used in ...
Background: Levosimendan is a calcium sensitizer and K+-ATP channel opener with inotropic and vasodi...
Background: Previous studies comparing levosimendan vs. dobutamine have revealed that levosimendan i...
Levosimendan is a new inotropic agent licensed in 10 European countries (Simdax, Orion Pharma, Finla...
International audienceLevosimendan is a new inodilatory agent with calcium sensitizing activity. A m...
Heart failure is characterised by decreased cardiac output, which results in the development of both...
Background: Right ventricular (RV) dysfunction complicates advanced left ventricular (LV) heart fail...
In heart failure, positive inotropes that increase the heart's energy requirements (digoxin, phospho...
Aims: To evaluate the safety and efficacy of levosimendan in patients with left ventricular failure ...
Background: Right ventricular (RV) dysfunction complicates advanced left ventricular (LV) heart fail...
WOS: 000252154900030PubMed ID: 17316845Background: Levosimendan is a novel positive inotropic calciu...
Calcium sensitizers also improve cardiac function by increasing the contraction of the myocardium wi...
Severe heart failure represents a major source of morbidity and mortality. Poor right ventricular fu...
Abstract BACKGROUND: Levosimendan (L) is used in clinical practice for the treatment of severe hear...
BackgroundLevosimendan is a new inodilatory agent with calcium sensitizing activity. A major concern...
International audienceWHAT IS KNOWN AND OBJECTIVE: Positive inotropic agents are frequently used in ...
Background: Levosimendan is a calcium sensitizer and K+-ATP channel opener with inotropic and vasodi...
Background: Previous studies comparing levosimendan vs. dobutamine have revealed that levosimendan i...
Levosimendan is a new inotropic agent licensed in 10 European countries (Simdax, Orion Pharma, Finla...
International audienceLevosimendan is a new inodilatory agent with calcium sensitizing activity. A m...
Heart failure is characterised by decreased cardiac output, which results in the development of both...
Background: Right ventricular (RV) dysfunction complicates advanced left ventricular (LV) heart fail...
In heart failure, positive inotropes that increase the heart's energy requirements (digoxin, phospho...
Aims: To evaluate the safety and efficacy of levosimendan in patients with left ventricular failure ...